These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32557987)

  • 1. An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
    Kanda M; Koike M; Iwata N; Shimizu D; Tanaka C; Hattori N; Hayashi M; Yamada S; Omae K; Nakayama G; Kodera Y
    Oncologist; 2020 Nov; 25(11):e1650-e1654. PubMed ID: 32557987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy with S-1 plus cisplatin for esophageal squamous cell carcinoma.
    Takahashi T; Kaneoka Y; Maeda A; Takayama Y; Seita K
    Updates Surg; 2022 Apr; 74(2):675-683. PubMed ID: 34559400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
    Ohnuma H; Sato Y; Hayasaka N; Matsuno T; Fujita C; Sato M; Osuga T; Hirakawa M; Miyanishi K; Sagawa T; Fujikawa K; Ohi M; Okagawa Y; Tsuji Y; Hirayama M; Ito T; Nobuoka T; Takemasa I; Kobune M; Kato J
    Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
    Tanaka Y; Yoshida K; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K
    Cancer Sci; 2016 Jun; 107(6):764-72. PubMed ID: 27061001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
    Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
    Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial.
    Kanda M; Shimizu D; Miyata K; Maeda O; Tanaka C; Inokawa Y; Hattori N; Hayashi M; Ando M; Kuwatsuka Y; Murotani K; Nakayama G; Koike M; Ando Y; Ebata T; Kodera Y
    Contemp Clin Trials Commun; 2021 Dec; 24():100853. PubMed ID: 34820548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to chemotherapy could predict the prognosis of esophageal squamous cell carcinoma treated with neoadjuvant docetaxel, cisplatin, and fluorouracil (DCF) followed by surgery: long-term results in a single institute.
    Sato Y; Mori K; Atsumi S; Sakamoto K; Oya S; Okamoto A; Urabe M; Miwa Y; Yajima S; Yagi K; Nomura S; Yamashita H; Seto Y
    Esophagus; 2024 Oct; 21(4):514-522. PubMed ID: 38987434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
    Loc NVV; Vuong NL; Trung LV; Trung TT
    J Gastrointest Cancer; 2023 Dec; 54(4):1240-1251. PubMed ID: 36723785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus.
    Yamagata Y; Saito K; Hirano K; Oya M
    World J Surg Oncol; 2020 Sep; 18(1):252. PubMed ID: 32962718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Neoadjuvant 5-Fluorouracil and Cisplatin Therapy in Patients with Clinical Stage II/III Esophageal Squamous Cell Carcinoma.
    Konishi H; Fujiwara H; Shiozaki A; Shoda K; Kosuga T; Kubota T; Okamoto K; Otsuji E
    Anticancer Res; 2018 Feb; 38(2):1017-1023. PubMed ID: 29374735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial.
    Zheng Y; Liang G; Yuan D; Liu X; Ba Y; Qin Z; Shen S; Li Z; Sun H; Liu B; Gao Q; Li P; Wang Z; Liu S; Zhu J; Wang H; Ma H; Liu Z; Zhao F; Zhang J; Zhang H; Wu D; Qu J; Ma J; Zhang P; Ma W; Yan M; Yu Y; Li Q; Zhang J; Xing W
    Cancer Commun (Lond); 2024 Oct; 44(10):1214-1227. PubMed ID: 39221992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
    Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
    Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907).
    Yokota T; Ando N; Igaki H; Shinoda M; Kato K; Mizusawa J; Katayama H; Nakamura K; Fukuda H; Kitagawa Y
    Oncology; 2015; 89(3):143-51. PubMed ID: 25895447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
    Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
    Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
    Okada N; Fujii S; Fujita T; Kanamori J; Kojima T; Hayashi R; Daiko H
    Surgery; 2016 Feb; 159(2):441-50. PubMed ID: 26391150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and S-1 for Resectable Advanced Esophageal Cancer.
    Hayata K; Ojima T; Nakamori M; Nakamura M; Katsuda M; Kitadani J; Takeuchi A; Tabata H; Maruoka S; Yamaue H
    Anticancer Res; 2018 Sep; 38(9):5267-5273. PubMed ID: 30194177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
    Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
    BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.